agCapture 3.2 Delivers on the Promise of Real Unification of Data Management Processes
ArisGlobal, a leading provider of solutions to the life sciences industry, has announced the immediate availability of agCapture™ 3.2, the newest release of ArisGlobal’s innovative EDC (Electronic Data Capture) system, fully unified with ePRO (electronic Patient Reported Outcome) RTSM (Randomization and Trial Supply Management), IWRS (Interactive Web Response System) and medical coding, and seamlessly integrated with CTMS (Clinical Trial Management System). agCapture is offered either as an on-premise or cloud solution.
“Trial sponsors are constantly searching for ways to reduce study costs and improve efficiencies while adhering to compliance requirements,” stated Simon Sparkes, executive vice president, ArisGlobal. “agCapture is simply a stand-out EDC system that is not only unified with our advanced ePro, RTSM and IWRS solutions, but is now fully integrated with CTMS using CDISC ODM (Clinical Data Interchange Standards Consortium Operational Data Model) standards as the basis of the integration. There is quite simply no other clinical drug development platform to match the ArisGlobal eClinical solution suite.”
agCapture 3.2 delivers many key features and enhancements that ensure a successful clinical study:
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.